Navigation Links
Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Date:12/10/2012

).

Boehringer Ingelheim intends to begin recruitment of a Phase III study (NCT01721876) to assess the efficacy and safety of volasertib in combination with LDAC compared with LDAC alone in early 2013.  The planned Phase III trial, POLO-AML-2, will enroll eligible patients aged 65 or older with previously untreated AML who are ineligible for intensive remission induction therapy.6  For additional information on the trial, please visit ClinicalTrials.gov.

About Volasertib
Volasertib, an investigational inhibitor of polo-like kinase (Plk), is one of several late-stage compounds that Boehringer Ingelheim is currently evaluating in clinical trials for various solid tumors and hematological cancers.

Of the company's ongoing research in cell cycle inhibition, the volasertib clinical development program is the furthest advanced. Boehringer Ingelheim is one of the first companies to advance Plk inhibitors into clinical development.

Volasertib is designed to inhibit the activity of Plk1, an enzyme that regulates cell division (mitosis).  This inhibition is intended to result in prolonged cell cycle arrest and ultimately cell death (apoptosis).7

Volasertib is not approved by the FDA; its safety and efficacy have not been established.

About Acute Myeloid Leukemia (AML)
AML is a cancer of the bone marrow and the blood.8  It is one of the most common types of leukemia in adults, accounting for 25 percent of all adult leukemias in the Western world,9 and has one of the lowest survival rates of all leukemias.2

AML is primarily a disease of later adulthood; the average age of an AML patient is 65 years.10  In patients diagnosed with AML at age 65 or older, the prognosis is poor.5

About Boehringer Ingelh
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Equine Research Awards
2. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
3. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
4. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 A pharmaceutical executive in the ... three issues he wanted the research and consulting firm ... personnel (especially for secondary research) to maximize efficiency and ... increased workload , Automation of market research processes ... , How to implement and manage those automated systems ...
(Date:9/19/2014)... VIEW, Calif. , Sept. 19, 2014 Today, ... in capital from Xiaomi Ventures, Ltd. for its first ... used to continue expanding iHealth,s global reach, accelerate growth ... resources.  As part of the investment, Xiaomi Ventures will ... the areas of cloud infrastructure and ecommerce. ...
(Date:9/19/2014)... , September 19, 2014 ... Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture ... Users (Hospitals), Advanced technologies - Global Forecast to ... is poised to reach $19,786.3 Million by 2019 ... of 6.8% from 2014 to 2019. ...
Breaking Medicine Technology:In Era of Competing Needs, Market Research Groups Under Pressure to Utilize Automation and External Staffing 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... , WALTHAM, Mass. , July 26 Repligen Corporation (Nasdaq: ... the first quarter of fiscal year 2011, on Thursday, August 5th, 2010 ... Walter C. Herlihy , Ph.D., will host a conference call and webcast on ... results and provide a quarterly update on the Company. , ...
... Circle Biologics®, Inc. has announced a technological break-through in regenerative ... single device platform is the first of its kind to ... in one point-of-care device. , ... The APC patented design (which has ...
Cached Medicine Technology:Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results 2Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results 3Circle Biologics® Introduces Innovation in Medical Devices 2
(Date:9/20/2014)... Lifeinsurancequoteterm.net has released a new blog post ... insurance plan provides for vulnerable family members. , ... a top priority for every provider. It is now ... examinations and visiting a doctor. , Life insurance ... coverage up to $300,000, but only to healthy applicants. ...
(Date:9/20/2014)... New PharmaPoint Drug Evaluation report, “Symbicort ... The asthma market saw very slow growth over ... with relatively efficacious standard therapies, such as short-acting ... long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has ... launch of seven novel targeted biologic agents and ...
(Date:9/20/2014)... have advised their patients against drinking coffee and wine. Dr. ... advice and changing his stance after considering two recent studies ... health. “There’s good news and great news,” says Dr. Wells, ... against gum disease, and red wine can help fight cavities!” ... September 2014 issue of Boston University School of Medicine ...
(Date:9/20/2014)... QueenBeeTickets.com is ready to offer discount Ariana ... will visit many cities in North America next year ... April. , Click Here to view the ... , The star’s fans are not going to want ... singer in a live performance. Ariana Grande concert tickets ...
(Date:9/20/2014)... “Motherhood is a wonderful gift and a huge ... latest article , “We know that you want to care ... we want to do as well.” , The article explains ... from their Family Physicians who practice obstetrics while pregnant, during ... , To learn more about Community Health Center of Snohomish ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2
... Beginning, March 17, 2009, the first of two effective ... Final Rule goes into effect. This final rule ... Version 4010A1 and National Council for Prescription Drug Programs ... transactions. Compliance with these standards is mandatory by ...
... Quantum Group, Inc. (NYSE Amex: QGP ) ( ... received notice on March 17, 2009 from the NYSE Amex ... it is not in compliance with Section 1003(a)(iv) of the ... sustained losses which are so substantial in relation to its ...
... may be driving the trend, doctors say , , FRIDAY, March ... reporting a sharp increase in the number of vasectomies performed ... many of his clients are from the beleaguered financial industry. ... both to a decreased desire to have children because of ...
... rigorous environmental cleaning intervention can reduce the transmission of ... organisms in hospital intensive care units (ICUs), according to ... of the Society for Healthcare Epidemiology of America (SHEA). ... reduced the spread of MRSA to patients exposed to ...
... for decades as a significant problem affecting astronauts. ... gravity is causing astronauts on the International Space Station ... in key regions of the body each month than ... time back here on Earth., Now, by simulating spaceflight ...
... implications for public safety, experts say , , FRIDAY, ... percent of candidates for fire and ambulance services ... situation that has major consequences for public health ... and musculoskeletal injury are important causes of [disability ...
Cached Medicine News:Health News:Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution 2Health News:Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution 3Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 2Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 3Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 4Health News:The Quantum Group Receives a NYSE Amex Notification of a Listing Deficiency 5Health News:With the Economy Down, Vasectomy Rates Are Up 2Health News:Environmental Cleaning Intervention Reduces Transmission of Multidrug-Resistant Organisms in ICUs 2Health News:University of Washington scientists one step closer to stopping bone loss during spaceflight 2Health News:Most New EMS Recruits Overweight or Obese 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: